Kentaro Nishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kentaro Nishi has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Koichi Kamei
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
17 shared publicationsMasao Ogura
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
16 shared publicationsKentaro Ide
Division of Critical Care Medicine, National Center for Child Health and Development, Tokyo, Japan
8 shared publicationsMisaki Akiyama
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
7 shared publicationsSatoshi Okada
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
7 shared publicationsTomoya Kaneda
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
7 shared publications
Latest Publications
- 12 August 2026
- Published by Springer Nature in Pediatric Nephrology
- p. 1-10
Acute kidney diseases and disorders in children with bloodstream infection: frequency, predictors, and outcomes
- 12 August 2026
- Published by Springer Nature in Pediatric Nephrology
- p. 1-10
Acute kidney diseases and disorders in children with bloodstream infection: frequency, predictors, and outcomes
- Open Access
- 6 July 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (3)
Pseudohypoaldosteronism associated with mitochondrial dysfunction in Angelman syndrome
- 6 July 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (3)
Open AccessPseudohypoaldosteronism associated with mitochondrial dysfunction in Angelman syndrome
- 12 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (12) , 4423-4432
Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome
Mycophenolate mofetil (MMF) as maintenance therapy after rituximab treatment is effective in preventing relapses in children with complicated frequently relapsing or steroid-dependent nephrotic syndrome. However, once sustained remission has been achieved by MMF, the outcomes and risk of relapse after discontinuing MMF remain unclear. We conducted a two-center, retrospective study of patients with childhood-onset frequently relapsing or steroid-dependent nephrotic syndrome who discontinued MMF because of sustained remission for ≥ 2 years on maintenance MMF after rituximab treatment. Relapse, additional treatment, and risk factors for relapses after MMF discontinuation were analyzed. Sixty patients were enrolled. After tapering or discontinuation of MMF, 35 (58%) patients relapsed, and the median time from tapering to relapse was 276 days. The 50% relapse-free survival was 1.5 years using the Kaplan-Meier method. After relapses, 30 (86%) patients required reinitiation of immunosuppressants or additional rituximab treatment. The history of initial steroid-resistant nephrotic syndrome, relapses < 10 times before the first rituximab treatment with immunosuppressants, and a longer period between the last B-cell recovery and tapering MMF were significantly associated with a lower risk of relapse in a multivariate analysis using the Cox proportional hazards model (all p < 0.05). Discontinuation of MMF may be considered in selected patients with sustained remission after rituximab treatment, particularly those with identified low-risk factors for relapse. The timing of discontinuation should be individualized according to these factors and patient-specific considerations because resumption of immunosuppressants or additional rituximab treatment is frequently required after relapse following MMF discontinuation.
- 12 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (12) , 4423-4432
Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome
Mycophenolate mofetil (MMF) as maintenance therapy after rituximab treatment is effective in preventing relapses in children with complicated frequently relapsing or steroid-dependent nephrotic syndrome. However, once sustained remission has been achieved by MMF, the outcomes and risk of relapse after discontinuing MMF remain unclear. We conducted a two-center, retrospective study of patients with childhood-onset frequently relapsing or steroid-dependent nephrotic syndrome who discontinued MMF because of sustained remission for ≥ 2 years on maintenance MMF after rituximab treatment. Relapse, additional treatment, and risk factors for relapses after MMF discontinuation were analyzed. Sixty patients were enrolled. After tapering or discontinuation of MMF, 35 (58%) patients relapsed, and the median time from tapering to relapse was 276 days. The 50% relapse-free survival was 1.5 years using the Kaplan-Meier method. After relapses, 30 (86%) patients required reinitiation of immunosuppressants or additional rituximab treatment. The history of initial steroid-resistant nephrotic syndrome, relapses < 10 times before the first rituximab treatment with immunosuppressants, and a longer period between the last B-cell recovery and tapering MMF were significantly associated with a lower risk of relapse in a multivariate analysis using the Cox proportional hazards model (all p < 0.05). Discontinuation of MMF may be considered in selected patients with sustained remission after rituximab treatment, particularly those with identified low-risk factors for relapse. The timing of discontinuation should be individualized according to these factors and patient-specific considerations because resumption of immunosuppressants or additional rituximab treatment is frequently required after relapse following MMF discontinuation.
- Open Access
- 20 April 2026
- Published by Springer Nature in Research Square
Acute kidney diseases and disorders in children with bloodstream infection: frequency, predictors, and outcomes
Background and hypothesis: Pediatric acute kidney diseases and disorders (AKD) are a new concept defined as kidney damage lasting 7–90 days from onset. Data on AKD after bloodstream infection are limited. Methods This single-center, retrospective observational study included patients aged < 20 years with BSI who were subsequently diagnosed with acute kidney injury (AKI) and/or AKD between 1 May 2013 and 31 May 2023. The index day was the date of the first positive blood culture. AKI (days 0–7) and AKD (days 7–90) were defined according to the Kidney Disease: Improving Global Outcomes/Acute Disease Quality Initiative criteria. Patients were categorized as those with AKI without AKD, AKD with AKI, and AKD without AKI. Primary comparisons included AKD (with/without AKI) versus AKI without AKD. Logistic regression analyses were conducted to identify predictors of AKD. Results Among 1427 patients with positive blood cultures, 197 developed kidney dysfunction. The final cohort comprised 96 patients, including 41 patients (43%) who developed AKD. In the final cohort, 55 patients had AKI without AKD, 33 patients had AKD with AKI, and 8 patients had AKD without AKI. By multivariable logistic regression analysis, younger age (odds ratio, 0.91; 95% confidence interval, 0.84–0.99; P = 0.046) was independently associated with AKD after adjusting for intensive care unit onset, glycopeptide exposure, and white blood cell count. Compared with AKI without AKD (0/55), those with AKD (with/without AKI) had higher rates of death (6/41, 15%) and major adverse kidney events at days 30 (7/41, 17%) and 90 (8/41, 20%). All adverse outcomes occurred in the AKD with AKI subgroup. Conclusion In children with bloodstream infection-associated kidney dysfunction, AKD occurred in a substantial proportion, including those not meeting the AKI criteria. Younger age was associated with AKD development.
- 20 April 2026
- Published by Springer Nature in Research Square
Open AccessAcute kidney diseases and disorders in children with bloodstream infection: frequency, predictors, and outcomes
Background and hypothesis: Pediatric acute kidney diseases and disorders (AKD) are a new concept defined as kidney damage lasting 7–90 days from onset. Data on AKD after bloodstream infection are limited. Methods This single-center, retrospective observational study included patients aged < 20 years with BSI who were subsequently diagnosed with acute kidney injury (AKI) and/or AKD between 1 May 2013 and 31 May 2023. The index day was the date of the first positive blood culture. AKI (days 0–7) and AKD (days 7–90) were defined according to the Kidney Disease: Improving Global Outcomes/Acute Disease Quality Initiative criteria. Patients were categorized as those with AKI without AKD, AKD with AKI, and AKD without AKI. Primary comparisons included AKD (with/without AKI) versus AKI without AKD. Logistic regression analyses were conducted to identify predictors of AKD. Results Among 1427 patients with positive blood cultures, 197 developed kidney dysfunction. The final cohort comprised 96 patients, including 41 patients (43%) who developed AKD. In the final cohort, 55 patients had AKI without AKD, 33 patients had AKD with AKI, and 8 patients had AKD without AKI. By multivariable logistic regression analysis, younger age (odds ratio, 0.91; 95% confidence interval, 0.84–0.99; P = 0.046) was independently associated with AKD after adjusting for intensive care unit onset, glycopeptide exposure, and white blood cell count. Compared with AKI without AKD (0/55), those with AKD (with/without AKI) had higher rates of death (6/41, 15%) and major adverse kidney events at days 30 (7/41, 17%) and 90 (8/41, 20%). All adverse outcomes occurred in the AKD with AKI subgroup. Conclusion In children with bloodstream infection-associated kidney dysfunction, AKD occurred in a substantial proportion, including those not meeting the AKI criteria. Younger age was associated with AKD development.
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1)
Efficacy and Safety of Alteplase Use for Venous Catheter Thrombosis in Pediatric Patients―a Single Center Study
Background: Urokinase is used as a thrombolytic agent to treat catheter thrombosis. However, since 2022, the supply of urokinase has diminished, and we have been using alteplase as an alternative, although its use for treating catheter thrombosis is off‐label in Japan. Methods: We performed a single‐center, retrospective study on pediatric patients with central venous catheters (CVCs), peripherally inserted central catheters (PICCs), and central venous ports (CVPs) who received alteplase for catheter thrombosis at our facility (May 2023–October 2025). Treatment involved filling the catheter (volume: 1–1.5 mL) with 600,000 U/mL (1 mg/mL) of alteplase solution and leaving it for approximately 40 min. Efficacy was evaluated as follows: (1) success on the first dose, (2) success after two or three doses, or (3) no success. (1) and (2) were defined as effective. Results: We evaluated 84 alteplase administrations in 31 patients (CVCs: 47, PICCs: 27, CVPs: 10). Success on the first dose was achieved in 55% of cases and success after two or three doses in 20% of cases, resulting in an overall efficacy rate of 75% (CVCs: 72%, PICCs: 93%, CVPs: 40%). No adverse events were observed. Conclusions: Alteplase was generally effective for treating catheter thrombosis. However, results suggest that it is less effective in CVPs than in CVCs and PICCs, and a larger sample size is necessary for confirmation. We recommend that alteplase be approved for treating catheter thrombosis in Japan.
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1)
Efficacy and Safety of Alteplase Use for Venous Catheter Thrombosis in Pediatric Patients―a Single Center Study
Background: Urokinase is used as a thrombolytic agent to treat catheter thrombosis. However, since 2022, the supply of urokinase has diminished, and we have been using alteplase as an alternative, although its use for treating catheter thrombosis is off‐label in Japan. Methods: We performed a single‐center, retrospective study on pediatric patients with central venous catheters (CVCs), peripherally inserted central catheters (PICCs), and central venous ports (CVPs) who received alteplase for catheter thrombosis at our facility (May 2023–October 2025). Treatment involved filling the catheter (volume: 1–1.5 mL) with 600,000 U/mL (1 mg/mL) of alteplase solution and leaving it for approximately 40 min. Efficacy was evaluated as follows: (1) success on the first dose, (2) success after two or three doses, or (3) no success. (1) and (2) were defined as effective. Results: We evaluated 84 alteplase administrations in 31 patients (CVCs: 47, PICCs: 27, CVPs: 10). Success on the first dose was achieved in 55% of cases and success after two or three doses in 20% of cases, resulting in an overall efficacy rate of 75% (CVCs: 72%, PICCs: 93%, CVPs: 40%). No adverse events were observed. Conclusions: Alteplase was generally effective for treating catheter thrombosis. However, results suggest that it is less effective in CVPs than in CVCs and PICCs, and a larger sample size is necessary for confirmation. We recommend that alteplase be approved for treating catheter thrombosis in Japan.
- 14 November 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (3) , 787-799
Prolonged hypotension in children with bilateral kidney absence: a case series and pathophysiologic insights
Background The renin–angiotensin–aldosterone system is essential for blood pressure regulation, and its absence in children with bilateral kidney loss predisposes them to hypotension unresponsive to standard therapies. However, the longer-term hemodynamic consequences and neurologic risks in this setting remain poorly understood. Methods We report three pediatric patients with bilateral congenital or acquired kidney absence that developed prolonged hypotension unresponsive to multiple antihypotensive therapy. A systematic literature review identified seven additional cases. The clinical features, interventions, and outcomes are descriptively summarized for these 10 patients. Results All three patients exhibited hypotension lasting 6–28 days despite preserved cardiac function without hypovolemia. In the combined literature review of 10 patients, the median age at hypotension onset was 7 months (range, 1–48 months). The etiology of kidney loss was congenital in 2 patients and bilateral nephrectomy in 8 patients. The median interval between kidney loss and hypotension onset was 14 days (range, 0 days–3 years). Among the 10 patients, blood pressure normalized in 8, of whom 4 survived without neurologic complications. Four patients developed hypoxic–ischemic encephalopathy. Five patients died, including three with neurologic complications. Management strategies included fluid overload, vasopressors, and midodrine. Angiotensin II was associated with favorable outcomes in two cases. Conclusions Children with bilateral kidney absence can recover from prolonged hypotension; however, this condition is associated with an increased risk of neurologic complications. Careful monitoring and supportive strategies, including approaches reported to be associated with recovery such as Angiotensin II or fluid overload, may help minimize risk. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 14 November 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (3) , 787-799
Prolonged hypotension in children with bilateral kidney absence: a case series and pathophysiologic insights
Background The renin–angiotensin–aldosterone system is essential for blood pressure regulation, and its absence in children with bilateral kidney loss predisposes them to hypotension unresponsive to standard therapies. However, the longer-term hemodynamic consequences and neurologic risks in this setting remain poorly understood. Methods We report three pediatric patients with bilateral congenital or acquired kidney absence that developed prolonged hypotension unresponsive to multiple antihypotensive therapy. A systematic literature review identified seven additional cases. The clinical features, interventions, and outcomes are descriptively summarized for these 10 patients. Results All three patients exhibited hypotension lasting 6–28 days despite preserved cardiac function without hypovolemia. In the combined literature review of 10 patients, the median age at hypotension onset was 7 months (range, 1–48 months). The etiology of kidney loss was congenital in 2 patients and bilateral nephrectomy in 8 patients. The median interval between kidney loss and hypotension onset was 14 days (range, 0 days–3 years). Among the 10 patients, blood pressure normalized in 8, of whom 4 survived without neurologic complications. Four patients developed hypoxic–ischemic encephalopathy. Five patients died, including three with neurologic complications. Management strategies included fluid overload, vasopressors, and midodrine. Angiotensin II was associated with favorable outcomes in two cases. Conclusions Children with bilateral kidney absence can recover from prolonged hypotension; however, this condition is associated with an increased risk of neurologic complications. Careful monitoring and supportive strategies, including approaches reported to be associated with recovery such as Angiotensin II or fluid overload, may help minimize risk. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 22 October 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (3) , 845-852
Neonatal acute kidney disease in the National Center for Child Health and Development (NCCHD)-neoAKI cohort: risk factors and prognostic outcomes
Background Acute kidney disease (AKD) is defined as kidney dysfunction lasting 7–90 days after the onset of acute kidney injury (AKI). Although widely recognized in adults and children, its significance in neonates is unclear. We aimed to investigate the risk factors and outcomes of neonatal AKD in a cohort of neonates with AKI. Methods We performed a retrospective cohort study at a tertiary NICU in Japan. Among 345 neonates with AKI between 2014 and 2024, 280 were included after excluding cases with congenital kidney disease, early death (< 7 days), or missing data. AKD was defined by KDIGO/ADQI criteria. We compared clinical features and outcomes between neonates with and without AKD and used multivariable logistic regression to identify predictors. Results Of 280 neonates with AKI, 85 (30%) developed AKD. Compared to non-AKD neonates, those with AKD had higher 90-day mortality (8% vs. 2%, P = 0.005) and MAKE90 (17% vs. 7%, P = 0.014). Chronic lung disease (78% vs. 50%, P < 0.001) and intraventricular hemorrhage (38% vs. 16%, P = 0.002) were also more common in the AKD group. In multivariable analysis, aminoglycoside exposure (OR = 2.04; 95% CI, 1.07–4.04; P = 0.031) and lower birth weight (per 100 g) (OR = 2.73; 95% CI, 1.11–1.22; P = 0.002) were independently associated with AKD. Conclusion Neonatal AKD was common and associated with increased mortality and major adverse kidney events. Our findings support AKD as a useful concept for identifying high-risk neonates and highlight the need for long-term kidney monitoring in this vulnerable population. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 22 October 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (3) , 845-852
Neonatal acute kidney disease in the National Center for Child Health and Development (NCCHD)-neoAKI cohort: risk factors and prognostic outcomes
Background Acute kidney disease (AKD) is defined as kidney dysfunction lasting 7–90 days after the onset of acute kidney injury (AKI). Although widely recognized in adults and children, its significance in neonates is unclear. We aimed to investigate the risk factors and outcomes of neonatal AKD in a cohort of neonates with AKI. Methods We performed a retrospective cohort study at a tertiary NICU in Japan. Among 345 neonates with AKI between 2014 and 2024, 280 were included after excluding cases with congenital kidney disease, early death (< 7 days), or missing data. AKD was defined by KDIGO/ADQI criteria. We compared clinical features and outcomes between neonates with and without AKD and used multivariable logistic regression to identify predictors. Results Of 280 neonates with AKI, 85 (30%) developed AKD. Compared to non-AKD neonates, those with AKD had higher 90-day mortality (8% vs. 2%, P = 0.005) and MAKE90 (17% vs. 7%, P = 0.014). Chronic lung disease (78% vs. 50%, P < 0.001) and intraventricular hemorrhage (38% vs. 16%, P = 0.002) were also more common in the AKD group. In multivariable analysis, aminoglycoside exposure (OR = 2.04; 95% CI, 1.07–4.04; P = 0.031) and lower birth weight (per 100 g) (OR = 2.73; 95% CI, 1.11–1.22; P = 0.002) were independently associated with AKD. Conclusion Neonatal AKD was common and associated with increased mortality and major adverse kidney events. Our findings support AKD as a useful concept for identifying high-risk neonates and highlight the need for long-term kidney monitoring in this vulnerable population. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 3 September 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (12) , 1829-1839
Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome
Background Maintenance therapy using immunosuppressive agents after rituximab can be effective for sustaining remission in childhood-onset refractory frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome (FRNS/SDNS). We evaluated the long-term outcome of mycophenolate mofetil (MMF) after rituximab. Methods We conducted a multicenter, retrospective cohort study of patients with childhood-onset refractory FRNS/SDNS who received MMF as maintenance therapy after a single dose of rituximab and were followed up ≥ 2 years at three pediatric renal centers. Relapses, additional treatment, risk factors for relapse, and adverse events were analyzed. Results We enrolled 106 patients, and the median follow-up was 7.2 years. Forty-seven (44%) patients had no relapse under MMF, and the 50% relapse-free survival was 3.2 years during MMF administration. Sixty-one (58%) patients required additional rituximab during the observation period. The mean annual number of relapses before the first rituximab treatment versus 1 year after rituximab initiation was 3.7 (standard deviation: 1.3) versus 0.4 (standard deviation: 0.8) times (p < 0.0001). Sixty-six of 74 (89%) patients could discontinue calcineurin inhibitors within 1 year after rituximab. MMF < 1000 mg/m2 was an independent significant risk factor for the first relapse (p = 0.03). No fatal adverse events and 23 episodes of infection requiring hospitalization were observed during the study period. Conclusions MMF after a single dose of rituximab is safe and effective in achieving a long relapse-free period and discontinuing a calcineurin inhibitor in patients with refractory FRNS/SDNS.
- 3 September 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (12) , 1829-1839
Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome
Background Maintenance therapy using immunosuppressive agents after rituximab can be effective for sustaining remission in childhood-onset refractory frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome (FRNS/SDNS). We evaluated the long-term outcome of mycophenolate mofetil (MMF) after rituximab. Methods We conducted a multicenter, retrospective cohort study of patients with childhood-onset refractory FRNS/SDNS who received MMF as maintenance therapy after a single dose of rituximab and were followed up ≥ 2 years at three pediatric renal centers. Relapses, additional treatment, risk factors for relapse, and adverse events were analyzed. Results We enrolled 106 patients, and the median follow-up was 7.2 years. Forty-seven (44%) patients had no relapse under MMF, and the 50% relapse-free survival was 3.2 years during MMF administration. Sixty-one (58%) patients required additional rituximab during the observation period. The mean annual number of relapses before the first rituximab treatment versus 1 year after rituximab initiation was 3.7 (standard deviation: 1.3) versus 0.4 (standard deviation: 0.8) times (p < 0.0001). Sixty-six of 74 (89%) patients could discontinue calcineurin inhibitors within 1 year after rituximab. MMF < 1000 mg/m2 was an independent significant risk factor for the first relapse (p = 0.03). No fatal adverse events and 23 episodes of infection requiring hospitalization were observed during the study period. Conclusions MMF after a single dose of rituximab is safe and effective in achieving a long relapse-free period and discontinuing a calcineurin inhibitor in patients with refractory FRNS/SDNS.
- Open Access
- 11 August 2025
- Published by Springer Nature in Research Square
Prolonged hypotension in children with bilateral kidney absence: a case series and pathophysiologic insights
Background The renin–angiotensin–aldosterone system is essential for blood pressure regulation, and its absence in children with bilateral kidney loss predisposes them to hypotension unresponsive to standard therapies. However, the longer-term hemodynamic consequences and neurologic risks in this setting remain poorly understood. Methods We report three pediatric patients with bilateral congenital or acquired kidney absence that developed prolonged hypotension unresponsive to multiple antihypotensive interventions. A systematic literature review identified seven additional cases. The clinical features, interventions, and outcomes were descriptively summarized for these 10 patients. Results All three patients exhibited hypotension lasting 6–28 days despite preserved cardiac function without hypovolemia. In the combined literature review of 10 patients, the median age at hypotension onset was 7 months (range, 1–48 months). The etiology of kidney loss was congenital in 2 patients and bilateral nephrectomy in 8 patients. The median interval between kidney loss and hypotension onset was 14 days (range, 0 days–3 years). Among the 10 patients, blood pressure normalized in 8 (80%), of whom 4 survived without neurologic complications. Four patients developed hypoxic–ischemic encephalopathy, and 5 patients (50%), including 3 with neurologic complications, died. Management strategies included fluid overload, vasopressors, and midodrine. Angiotensin II was associated with favorable outcomes in two cases. Conclusions Children with bilateral kidney absence can recover from prolonged hypotension; however, this condition is associated with an increased risk of neurologic complications. Sustained hemodynamic support is essential to minimize the risk of irreversible injury during the hypotensive period.
- 11 August 2025
- Published by Springer Nature in Research Square
Open AccessProlonged hypotension in children with bilateral kidney absence: a case series and pathophysiologic insights
Background The renin–angiotensin–aldosterone system is essential for blood pressure regulation, and its absence in children with bilateral kidney loss predisposes them to hypotension unresponsive to standard therapies. However, the longer-term hemodynamic consequences and neurologic risks in this setting remain poorly understood. Methods We report three pediatric patients with bilateral congenital or acquired kidney absence that developed prolonged hypotension unresponsive to multiple antihypotensive interventions. A systematic literature review identified seven additional cases. The clinical features, interventions, and outcomes were descriptively summarized for these 10 patients. Results All three patients exhibited hypotension lasting 6–28 days despite preserved cardiac function without hypovolemia. In the combined literature review of 10 patients, the median age at hypotension onset was 7 months (range, 1–48 months). The etiology of kidney loss was congenital in 2 patients and bilateral nephrectomy in 8 patients. The median interval between kidney loss and hypotension onset was 14 days (range, 0 days–3 years). Among the 10 patients, blood pressure normalized in 8 (80%), of whom 4 survived without neurologic complications. Four patients developed hypoxic–ischemic encephalopathy, and 5 patients (50%), including 3 with neurologic complications, died. Management strategies included fluid overload, vasopressors, and midodrine. Angiotensin II was associated with favorable outcomes in two cases. Conclusions Children with bilateral kidney absence can recover from prolonged hypotension; however, this condition is associated with an increased risk of neurologic complications. Sustained hemodynamic support is essential to minimize the risk of irreversible injury during the hypotensive period.
- Open Access
- 14 July 2025
- Published by Springer Nature in Research Square
Neonatal acute kidney disease in the NCCHD-neoAKI Cohort: risk factors and prognostic outcomes
Background: Acute kidney disease (AKD) is defined as kidney dysfunction lasting 7–90 days after an initiating event. Although widely recognized in adults and children, its significance in neonates is unclear. We aimed to investigate the risk factors and outcomes of neonatal AKD in a cohort of neonates with acute kidney injury (AKI). Methods: We performed a retrospective cohort study at a tertiary NICU in Japan. Among 345 neonates with AKI between 2014 and 2024, 280 were included after excluding cases with congenital kidney disease, early death (< 7 days), or missing data. AKD was defined by KDIGO/ADQI criteria. We compared clinical features and outcomes between neonates with and without AKD and used multivariable logistic regression to identify predictors. Results: Of 280 neonates with AKI, 85 (30%) developed AKD. Compared to non-AKD neonates, those with AKD had higher 90-day mortality (8% vs. 2%, P = 0.005) and MAKE90 (17% vs. 7%, P = 0.014). Chronic lung disease (78% vs. 50%, P < 0.001) and intraventricular hemorrhage (38% vs 16%, P = 0.002) were also more common in the AKD group. In multivariable analysis, aminoglycoside exposure (OR = 2.04; 95% CI, 1.07–4.04; P = 0.031) and lower birth weight (per 100 g) (OR = 2.73; 95% CI, 1.11–1.22; P = 0.002) were independently associated with AKD. Conclusion: Neonatal AKD was common and associated with increased mortality and major adverse kidney events. Our findings support AKD as a useful concept for identifying high-risk neonates and highlight the need for long-term kidney monitoring in this vulnerable population.
- 14 July 2025
- Published by Springer Nature in Research Square
Open AccessNeonatal acute kidney disease in the NCCHD-neoAKI Cohort: risk factors and prognostic outcomes
Background: Acute kidney disease (AKD) is defined as kidney dysfunction lasting 7–90 days after an initiating event. Although widely recognized in adults and children, its significance in neonates is unclear. We aimed to investigate the risk factors and outcomes of neonatal AKD in a cohort of neonates with acute kidney injury (AKI). Methods: We performed a retrospective cohort study at a tertiary NICU in Japan. Among 345 neonates with AKI between 2014 and 2024, 280 were included after excluding cases with congenital kidney disease, early death (< 7 days), or missing data. AKD was defined by KDIGO/ADQI criteria. We compared clinical features and outcomes between neonates with and without AKD and used multivariable logistic regression to identify predictors. Results: Of 280 neonates with AKI, 85 (30%) developed AKD. Compared to non-AKD neonates, those with AKD had higher 90-day mortality (8% vs. 2%, P = 0.005) and MAKE90 (17% vs. 7%, P = 0.014). Chronic lung disease (78% vs. 50%, P < 0.001) and intraventricular hemorrhage (38% vs 16%, P = 0.002) were also more common in the AKD group. In multivariable analysis, aminoglycoside exposure (OR = 2.04; 95% CI, 1.07–4.04; P = 0.031) and lower birth weight (per 100 g) (OR = 2.73; 95% CI, 1.11–1.22; P = 0.002) were independently associated with AKD. Conclusion: Neonatal AKD was common and associated with increased mortality and major adverse kidney events. Our findings support AKD as a useful concept for identifying high-risk neonates and highlight the need for long-term kidney monitoring in this vulnerable population.